MXJL06000001A - Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante. - Google Patents

Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante.

Info

Publication number
MXJL06000001A
MXJL06000001A MXJL06000001A MXJL06000001A MXJL06000001A MX JL06000001 A MXJL06000001 A MX JL06000001A MX JL06000001 A MXJL06000001 A MX JL06000001A MX JL06000001 A MXJL06000001 A MX JL06000001A MX JL06000001 A MXJL06000001 A MX JL06000001A
Authority
MX
Mexico
Prior art keywords
aqueous
meloxicam
solution
preparing
treatment
Prior art date
Application number
MXJL06000001A
Other languages
English (en)
Inventor
Arturo Jimenez Bayardo
Original Assignee
Arturo Jimenez Bayardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arturo Jimenez Bayardo filed Critical Arturo Jimenez Bayardo
Priority to MXJL06000001A priority Critical patent/MXJL06000001A/es
Publication of MXJL06000001A publication Critical patent/MXJL06000001A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un metodo para solubilizar un agente activo inhibidor selectivo de ciclooxigenasa-2 (COX-2), tal como meloxicam , y un metodo para preparar una solucion oftalmica a partir de meloxicam solubilizado para el tratamiento de diversas afecciones oculares. La presente invencion concierne ademas a una solucion oftalmica acuosa que resulta del metodo referido, la cual se caracteriza por su seguridad, inocuidad y eficacia en el tratamiento del paciente. La nueva solucion oftalmica acuosa se distingue porque su valor farmaceutico radica en el manejo de un vehiculo de facil acceso no solamente permite la solubilidad del meloxicam si no que tambien favorece una mayor tolerancia del paciente al tratamiento de su padecimiento en el ojo de su recuperacion post-quirurgica.
MXJL06000001A 2003-07-10 2006-01-10 Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante. MXJL06000001A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MXJL06000001A MXJL06000001A (es) 2003-07-10 2006-01-10 Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/MX2003/000054 WO2005004876A1 (es) 2003-07-10 2003-07-10 Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante
MXJL06000001A MXJL06000001A (es) 2003-07-10 2006-01-10 Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante.

Publications (1)

Publication Number Publication Date
MXJL06000001A true MXJL06000001A (es) 2006-04-11

Family

ID=34056954

Family Applications (1)

Application Number Title Priority Date Filing Date
MXJL06000001A MXJL06000001A (es) 2003-07-10 2006-01-10 Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante.

Country Status (6)

Country Link
US (1) US20070092539A1 (es)
EP (2) EP1972340A3 (es)
AU (1) AU2003243055A1 (es)
BR (1) BR0318395A (es)
MX (1) MXJL06000001A (es)
WO (1) WO2005004876A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2667945T3 (es) * 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
TR200809200A1 (tr) * 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
JP2012529509A (ja) * 2009-06-09 2012-11-22 ラックス・バイオサイエンシーズ・インコーポレイテッド 眼科用用途のための局所薬物送達システム
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
US20180168932A1 (en) * 2016-12-20 2018-06-21 Apotex Technologies Inc. Meloxicam Dosage Forms
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN115494174B (zh) * 2022-09-23 2024-03-29 南京瑞孚医药科技有限公司 一种高效液相色谱法检测美洛昔康中硫脲的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679135B1 (fr) * 1991-07-18 1995-05-19 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a adhesivite amelioree et leurs procedes de preparation.
EP0833622B8 (en) 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
EP1007049A1 (en) * 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
AU754064B2 (en) * 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
AU1548001A (en) * 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion

Also Published As

Publication number Publication date
WO2005004876A1 (es) 2005-01-20
EP1972340A2 (en) 2008-09-24
EP1972340A3 (en) 2008-11-26
BR0318395A (pt) 2006-08-01
EP1649858A1 (en) 2006-04-26
US20070092539A1 (en) 2007-04-26
AU2003243055A1 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
MXJL06000001A (es) Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante.
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2018013476A (es) Composiciones para tratar trastornos acido-base.
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
WO2005105037A3 (en) Use of a viscoelastic composition for treating increased intraocular pressure
BR0316753A (pt) Método de tratamento para disfunção sexual
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2012145428A3 (en) Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
MY199237A (en) Methods of treating ocular conditions
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
BR112017004729A2 (pt) processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
Kim et al. Successful Surgical Treatment of Feline Acute Bullous Keratopathy and Corneal Perforation with a Conjunctival Hood Graft
Hunter Aspirin/warfarin
CN103610676B (zh) 4-((吡啶-3-羧基)-氨基)-丁酸或其盐在制备治疗男性性功能勃起障碍疾病药物中的应用
Chang Calcium hydroxylapatite
Craig Complement C1 inhibitor protein
RU2004132138A (ru) Способ лечения внутриглазных кровоизлияний

Legal Events

Date Code Title Description
FA Abandonment or withdrawal